Chemours(US:CC) ZACKSยท2025-08-05 23:21Core Viewpoint - Chemours reported quarterly earnings of $0.58 per share, exceeding the Zacks Consensus Estimate of $0.46 per share, and showing an increase from $0.38 per share a year ago, indicating a strong earnings surprise of +26.09% [1] Group 1: Earnings Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - Chemours posted revenues of $1.62 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.98%, compared to $1.54 billion in the same quarter last year [2] - The earnings report reflects a significant improvement in earnings performance compared to the previous quarter, where the expected earnings were $0.19 per share, but the actual was $0.13, resulting in a surprise of -31.58% [1][2] Group 2: Stock Performance and Outlook - Chemours shares have declined approximately 27.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.50 for the coming quarter and $1.47 for the current fiscal year [4][7] - The Zacks Rank for Chemours is currently 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Group 3: Industry Context - The Chemical - Diversified industry, to which Chemours belongs, is currently ranked in the bottom 7% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Chemours' stock performance [5]